Introduction
============

In older patients, iron-deficiency anemia is associated with an elevated risk of mortality and various morbidities (such as cardiovascular disease and cognitive dysfunction).[@b1-cia-9-737] Treatment of this type of anemia is based on oral iron supplementation (with ferrous sulfate tablets in most cases). Although iron supplementation is generally well-tolerated, mucosal injury to the upper gastrointestinal tract following iron overdose has often been described, particularly in children.[@b2-cia-9-737],[@b3-cia-9-737] Iron overdose is thought to exert a direct, corrosive effect that causes mucosal necrosis and ulceration.[@b2-cia-9-737]--[@b5-cia-9-737] However, mucosal injury has very rarely been reported in patients receiving therapeutic dosages of ferrous sulfate, and the few case reports in the literature mainly concern gastric injury.[@b6-cia-9-737]

Here, we report the case of an elderly patient in whom oral ulceration was induced by direct, prolonged contact with ferrous sulfate. The presence of a causal relationship between mouth ulceration and ferrous sulfate was assessed in accordance with the current French guidelines.[@b7-cia-9-737] We also identified nine other cases of oral ulceration associated with ferrous sulfate in the French National Pharmacovigilance Database. To the best of our knowledge, this is the largest case series described to date.

Case report
===========

An 87-year-old woman with progressing Alzheimer's disease and deglutition disorders developed a large, irregular area of oral ulceration. The lesion extended from the side of the tongue to the floor of the mouth. The patient was being treated with ferrous sulfate (80 mg per day), esomeprazole (20 mg per day), macrogol (10 mg four times a day), and lysine acetylsalicylate (75 mg per day).

Histologic examination of a tissue sample from the ulcerated area revealed acute inflammatory granular and hemorrhagic features. Perls' staining revealed the presence of siderophages.

At the time of onset, no clear explanation for the symptoms had been found and various local treatments were ineffective. Once it was realized that the ferrous sulfate tablets given as an iron supplement were being crushed prior to administration (due to the patient's deglutition disorders), withdrawal of this treatment led to rapid resolution of the ulceration.

Review of the French National Pharmacovigilance Database
========================================================

We searched the French National Pharmacovigilance Database between July 1986 and July 2013 and found nine reports of mouth ulceration associated with the use of ferrous sulfate tablets ([Table 1](#t1-cia-9-737){ref-type="table"}). The French National Pharmacovigilance system was established in 1973. A network of 31 regional centers receives spontaneous reports of "serious and/or unexpected" adverse drug reactions from health care professionals. Eight of the nine patients were women. The patients' mean age was 81.5 years (range: 54--97 years). Dysphagia or prolonged presence of tablets in the mouth were reported in three cases and the use of crushed tablets was reported in two other cases. Ferrous sulfate was always the only medication suspected and all the cases of oral ulceration resolved or improved rapidly after withdrawal of this treatment. No cases of oral ulceration were associated with other iron salts (eg, iron fumarate and ascorbate, which are also widely prescribed) were found in the French National Pharmacovigilance Database. In accordance with the literature data mentioned, the database also featured cases of esophageal and gastric ulceration related to the administration of ferrous sulfate.

Discussion
==========

This case series shows that the risk of oral ulceration must be taken into account when ferrous sulfate tablets are administered to patients (and especially elderly patients) in whom cognitive impairments and/or deglutition disorders may cause the tablets to remain in the mouth for more than a few seconds. Furthermore, patients with dementia may have difficulty expressing discomfort and pain.

Only two other publications have reported that prolonged stasis of ferrous sulfate tablets in the mouth can cause chemical burns to the oral mucosa.[@b8-cia-9-737],[@b9-cia-9-737] In both reports, the patients presented senile dementia.[@b8-cia-9-737],[@b9-cia-9-737] In one case, tablet stasis in the mouth was thought to be due to torticollis associated with ankylosis of the right shoulder.[@b9-cia-9-737]

The mucosal damage caused by high local iron concentrations may be related to the formation of reactive oxygen species.[@b10-cia-9-737] Indeed, these species and free radicals have been implicated in mucosal alterations in gastric or intestinal injuries. The fact that some animal models of gastric ulceration are based on the administration of ferrous iron emphasizes the harmful effects of these salts on mucosal membranes.[@b11-cia-9-737]

The mucosal toxicity of ferrous sulfate has also been reported for the hypopharynx,[@b12-cia-9-737] the esophageal lumen,[@b13-cia-9-737] and (after inhalation of a tablet) the tracheobronchial tree.[@b14-cia-9-737],[@b15-cia-9-737]

Direct, prolonged contact with a tablet reportedly induces alterations in both the digestive and respiratory mucosae. The latter resulted from accidental inhalation and bronchial stenosis; after removal of the tablet, the resulting, massive hemoptysis lasted for several days.[@b15-cia-9-737]--[@b18-cia-9-737]

Conclusion
==========

The above-described cases show that care must be taken when administering iron salts to elderly patients. Iron supplementation is frequent in this population. The risk of mucosal toxicity may be increased by age- or disease-related dysphagia and/or cognitive impairment. It would be useful to specifically evaluate the incidence and severity of this adverse event and define the at-risk populations. Appropriate pharmaceutical formulations (such as syrups) should be administered to patients with deglutition disorders. The use of iron salts other than ferrous sulfate may be a better option for correcting anemia in at-risk patients.
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###### 

Summary of cases of mouth ulceration with a suspected causal relationship with the administration of ferrous sulfate tablets (either alone or in combination with other drugs)

  Case   Sex   Age (years)   Medical history                                                               Daily dose (mg)        Duration of drug exposure   Reported adverse event         Concomitant drugs                                                Other drugs implicated
  ------ ----- ------------- ----------------------------------------------------------------------------- ---------------------- --------------------------- ------------------------------ ---------------------------------------------------------------- ------------------------
  1      F     80            Anemia                                                                        80 (crushed tablets)   1 month                     Mouth ulceration, stomatitis   Lysine acetylsalicylate, pantoprazole                            None
  2      F     81            Anemia, arteritis, gastric ulcer, head leaning to the side, salivary stasis   80                     1 month                     Mouth ulceration               Amitriptylin E, clonazepam, omeprazole, fraxiparine              None
  3      F     80            Alzheimer's disease, cardiac insufficiency, hypertension, anemia, dysphagia   80 (crushed tablets)   Several years               Mouth ulceration               Amantadine, enalapril, lysine acetylsalicylate                   None
  4      F     82            Anemia                                                                        80                     1 day                       Mouth ulceration               Esomeprazole, clonazepam                                         None
  5      M     90            Anemia, bedridden patient                                                     80                     Unknown                     Mouth ulceration               --                                                               None
  6      F     83            Anemia, hypertension, diabetes, bladder cancer                                80                     14 days                     Mouth ulceration               Gliclazide, nicardipine, clomipramine, lysine acetylsalicylate   None
  7      F     85            Anemia, bedridden patient                                                     80                     Unknown                     Mouth ulceration               --                                                               None
  8      F     54            Facial paralysis, dysphagia                                                   80                     5 days                      Mouth ulceration               Clorazepate, omeprazole                                          None
  9      F     97            Anemia                                                                        80                     2 months                    Mouth ulceration               Ranitidine, lysine acetylsalicylate                              None

**Note:** Data from the French National Pharmacovigilance Database (1986--2013). -- no concomitant drugs in addition to trospium was reported taken by the patient.

**Abbreviations:** M, male; F, female.
